RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ChemoCentryx Stock

ChemoCentryx Net Income 2025

ChemoCentryx Net Income

261.07 M USD

Ticker

CCXI

ISIN

US16383L1061

WKN

A0NBM2

In 2025, ChemoCentryx's profit amounted to 261.07 M USD, a 145.1% increase from the 106.52 M USD profit recorded in the previous year.

The ChemoCentryx Net Income history

YEARNET INCOME (undefined USD)
2026e652.67
2025e261.07
2024e106.52
2023e-15.79
2022e-119.22
2021-131.76
2020-55.36
2019-55.49
2018-37.97
201717.86
2016-39.96
2015-47.31
2014-46.93
2013-38.67
2012-39.89
2011-4.62
2010-3.1
200915.62
2008-18.47
2007-15.69
2006-17.34

ChemoCentryx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ChemoCentryx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ChemoCentryx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ChemoCentryx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ChemoCentryx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ChemoCentryx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ChemoCentryx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ChemoCentryx’s growth potential.

ChemoCentryx Revenue, EBIT and net profit per share

DateChemoCentryx RevenueChemoCentryx EBITChemoCentryx Net Income
2026e1.3 B undefined885.83 M undefined652.67 M undefined
2025e841.57 M undefined354.33 M undefined261.07 M undefined
2024e412.67 M undefined144.57 M undefined106.52 M undefined
2023e224.88 M undefined-15.02 M undefined-15.79 M undefined
2022e73.85 M undefined-122.73 M undefined-119.22 M undefined
202132.22 M undefined-129.92 M undefined-131.76 M undefined
202064.89 M undefined-55.18 M undefined-55.36 M undefined
201936.13 M undefined-58.3 M undefined-55.49 M undefined
201842.88 M undefined-40.27 M undefined-37.97 M undefined
201782.5 M undefined16.49 M undefined17.86 M undefined
201611.94 M undefined-40.72 M undefined-39.96 M undefined
20150 undefined-47.69 M undefined-47.31 M undefined
20140 undefined-47.4 M undefined-46.93 M undefined
20136.06 M undefined-39.12 M undefined-38.67 M undefined
20125.42 M undefined-39.63 M undefined-39.89 M undefined
201131.67 M undefined-4.3 M undefined-4.62 M undefined
201034.86 M undefined-5.96 M undefined-3.1 M undefined
200949.74 M undefined15.7 M undefined15.62 M undefined
200824.09 M undefined-20.13 M undefined-18.47 M undefined
200720.74 M undefined-19.14 M undefined-15.69 M undefined
20068.11 M undefined-19.14 M undefined-17.34 M undefined

ChemoCentryx stock margins

The ChemoCentryx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ChemoCentryx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ChemoCentryx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ChemoCentryx's sales revenue. A higher gross margin percentage indicates that the ChemoCentryx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ChemoCentryx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ChemoCentryx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ChemoCentryx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ChemoCentryx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ChemoCentryx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ChemoCentryx Margin History

ChemoCentryx Gross marginChemoCentryx Profit marginChemoCentryx EBIT marginChemoCentryx Profit margin
2026e99.06 %68.35 %50.36 %
2025e99.06 %42.1 %31.02 %
2024e99.06 %35.03 %25.81 %
2023e99.06 %-6.68 %-7.02 %
2022e99.06 %-166.21 %-161.45 %
202199.06 %-403.17 %-408.87 %
202099.06 %-85.04 %-85.31 %
201999.06 %-161.36 %-153.58 %
201899.06 %-93.91 %-88.55 %
201799.06 %19.99 %21.65 %
201699.06 %-341.04 %-334.67 %
201599.06 %0 %0 %
201499.06 %0 %0 %
201399.06 %-645.54 %-638.12 %
201299.06 %-731.18 %-735.98 %
201199.06 %-13.58 %-14.59 %
201099.06 %-17.1 %-8.89 %
200999.06 %31.56 %31.4 %
200899.06 %-83.56 %-76.67 %
200799.06 %-92.29 %-75.65 %
200699.06 %-236 %-213.81 %

ChemoCentryx Aktienanalyse

What does ChemoCentryx do?

ChemoCentryx Inc. was founded in 1997 and is based in Mountain View, California. The company specializes in the development of medications for rare autoimmune diseases, cancer, and inflammation. Since its founding, ChemoCentryx Inc. has developed a variety of drug candidates, some of which are in clinical phases or as finished products. The business model of ChemoCentryx Inc. is based on the discovery and development of medications targeting chemokines and chemokine receptors. This technology allows for the regulation and control of inflammatory processes. The company also utilizes its proprietary Janus kinase inhibitors (JAK inhibitors) for the treatment of inflammatory diseases. ChemoCentryx Inc. has several business areas. The primary area is the research and development of medications that can be used as candidates against inflammatory, cancer, autoimmune, and fibrosis diseases. The second significant area is collaboration with international partners in the research and development of these medications. The company has also developed specialized tools and technologies to optimize its drug development processes. These techniques include high-throughput screening and X-ray crystallography technologies, as well as biomarker-based diagnostics. One important product of ChemoCentryx Inc. is Avacopan, an oral medication used in the treatment of ANCA-associated vasculitic diseases such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is a selective antagonist of the C5a receptor, which plays a central role in the inflammatory response. Clinical studies on the efficacy and safety of Avacopan have yielded promising results, and the medication has received Breakthrough Therapy Designation status from the US FDA. Additionally, ChemoCentryx Inc. has successfully identified candidates for the treatment of atopic dermatitis, lupus nephritis, and Crohn's disease. These products are still in the clinical development phase and have great potential to significantly improve the lives of patients suffering from these conditions. Overall, ChemoCentryx Inc. has made significant progress in the discovery and development of drugs that can combat inflammation and other chronic diseases. The company is well-positioned to expand its pipeline and bring additional breakthrough products to market that will play a crucial role in treating diseases that have been difficult to treat in the past. ChemoCentryx ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding ChemoCentryx's Profit Margins

The profit margins of ChemoCentryx represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ChemoCentryx's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating ChemoCentryx's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

ChemoCentryx's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When ChemoCentryx’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about ChemoCentryx stock

How much profit has ChemoCentryx made this year?

ChemoCentryx has made 261.07 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 145.1% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does ChemoCentryx publish its earnings?

ChemoCentryx publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of ChemoCentryx?

The profits of ChemoCentryx are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of ChemoCentryx?

You can learn more about the earnings of ChemoCentryx by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does ChemoCentryx pay?

Over the past 12 months, ChemoCentryx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ChemoCentryx is expected to pay a dividend of 0 USD.

What is the dividend yield of ChemoCentryx?

The current dividend yield of ChemoCentryx is .

When does ChemoCentryx pay dividends?

ChemoCentryx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ChemoCentryx?

ChemoCentryx paid dividends every year for the past 0 years.

What is the dividend of ChemoCentryx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ChemoCentryx located?

ChemoCentryx is assigned to the 'Health' sector.

Wann musste ich die Aktien von ChemoCentryx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ChemoCentryx from 7/23/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/23/2025.

When did ChemoCentryx pay the last dividend?

The last dividend was paid out on 7/23/2025.

What was the dividend of ChemoCentryx in the year 2024?

In the year 2024, ChemoCentryx distributed 0 USD as dividends.

In which currency does ChemoCentryx pay out the dividend?

The dividends of ChemoCentryx are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ChemoCentryx stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ChemoCentryx

Our stock analysis for ChemoCentryx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ChemoCentryx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.